Neuropsychiatric sequelae similar for severe COVID-19, SARI

Neuropsychiatric sequelae similar for severe COVID-19, SARI

The neuropsychiatric sequelae are similar for severe COVID-19 infection and for other severe acute respiratory infections (SARI), according to a study published online May 11 in JAMA Psychiatry.

Ashley Kieran Clift, M.B.B.S., from the University of Oxford in the United Kingdom, and colleagues quantified the of new-onset neuropsychiatric conditions and new neuropsychiatric medication prescriptions after discharge from a COVID-19-related hospitalization and compared them with risks after from hospitalization with other SARI among patients identified in databases from Jan. 24, 2020, to July 7, 2021.

The researchers found that 16,679 (0.02 percent) and 32,525 (0.03 percent) of the 8.38 million adults survived a hospital admission for SARI and COVID-19, respectively. Survivors of SARI and COVID-19 hospitalization had increased risks of subsequent neuropsychiatric disorders compared with the remaining population. The hazard ratios for anxiety were 1.86 and 2.36 for survivors of SARI and COVID-19 , respectively; the corresponding hazard ratios for dementia were 2.55 and 2.63. For all medications analyzed, the findings were similar; for example, the hazard ratios for first prescriptions of antidepressants were 2.55 and 3.24 for survivors of SARI and COVID-19, respectively. When directly comparing the COVID-19 group with the SARI group, there were no significant differences observed, apart from a lower risk of antipsychotic prescriptions in the COVID-19 group (hazard ratio, 0.80).

"These results may help refine our understanding of the postsevere COVID-19 phenotype and may inform postdischarge support for patients requiring hospital-based and for SARI regardless of causative pathogen," the authors write.

More information: Abstract/Full Text

Journal information: JAMA Psychiatry

Copyright © 2022 HealthDay. All rights reserved.

Citation: Neuropsychiatric sequelae similar for severe COVID-19, SARI (2022, May 11) retrieved 12 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Sickle cell disease may up risk for poor COVID-19 outcomes


Feedback to editors